

Lombardy Region approved the "agreement for innovation" scheme for the financing, together with the Ministry of Economic Development, of MolMed's project proposal "New CAR therapies for the treatment of cancer patients (NUCAR)".

Milan (Italy), October 1st 2019 – MolMed S.p.A. (MLMD.MI) (the "Company"), a biotechnology company focused on research, development, production and clinical validation of gene and cell therapies for the treatment of cancer and rare diseases, informs that the Council of the Lombardy Region yesterday approved the "agreement for innovation" scheme involving the Region, the Ministry of Economic Development (MiSE) and MolMed, with the scope to co-finance, in the form of a grant funding, the research costs of MolMed in the CAR (Chimeric Antigen Receptor) field.

Lombardy Region's resolution is part of the broader approval process for the project proposal, called "*New CAR therapies for the treatment of cancer patients (NUCAR)*" presented by MolMed to MiSE in order to access the "Fund for sustainable growth" ("Fondo per la crescita sostenibile"), currently under discussion and whose outcome will follow the presentation of the final projects by MolMed and MiSE's approval.

About MolMed

MolMed S.p.A. is a clinical stage biotech company focused on research, development, manufacturing and clinical validation of innovative therapies. MolMed is the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies ex vivo for its proprietary products (Zalmoxis™) as well as for third parties and/or in partnership (Strimvelis, an Orchard gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies.

MolMed's product portfolio includes proprietary anti-tumor therapies in both clinical and preclinical development: the Company is developing a new therapeutic platform based on Chimeric Antigen Receptor (CAR), both autologous and allogeneic; the most advanced product, CAR-T CD44v6, which in March 2019 received the authorization to start human clinical trials in onco-hematologic indications (AML and MM), following an extensive pre-clinical phase. The product is potentially effective also in several epithelial solid tumors.

In the field of allogeneic products, MolMed is developing a pipeline based on NK (Natural Killer) cells, following a research agreement signed in 2018 with Glycostem.

MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso.

For further information:

Ilaria Candotti

Investor Relations & Communication Manager

MolMed S.p.A.

+39 02 21277.205

investor.relations@molmed.com

Tommasina Cazzato

Press Office

Community Group

+39 345 7357751

tommasina.cazzato@communitygroup.it